ClinicalTrials.gg
RecruitingNCT07599774Updated Nov 10, 2026

Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor Impairments

An interventional study of High-definition transcranial direct stimulation: sham and High-definition transcranial direct stimulation: optimal in Hemiparetic Stroke, sponsored by Carle Foundation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Carle Foundation Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.

Planned enrollment
1,221st of 1,621
16 · median 40
Started
2026
with 104 others
No phase
1,124 of 1,995
270 open now
Primary completion
2027-03
later than 202 of 488 live
Registered
1,938th of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 1,221st largest by planned enrollment of the 1,621 interventional ones that give a count, is one of 105 that started in 2026, is one of 1,124 with no phase, reaches primary completion later than 202 of the 488 other live ones, and was the 1,938th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

386 more — sign in →

All 392 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

Non-invasive, non-pharmaceutical technologies that augment routine clinical practice for brain diseases and manage chronic symptoms have advanced rapidly over the past two decades. Among these, non-invasive brain stimulation such as transcranial direct current stimulation (tDCS) promotes neuroplasticity in injured brains, with fewer side effects and risks than invasive, implanted approaches such as deep-brain stimulation. Stimulating the brain can improve its function and help with recovery after a stroke. It has been a challenge to do this non-invasively. This is because the brain is reshaped after a stroke, and thus, it is difficult to find the right places to stimulate from the outside. In previous research, investigators found that optimal type and target of tDCS varied among subjects. The goal of this pilot trial is to test the feasibility of combining individually optimized, targeted high-definition tDCS (THD-tDCS) with rehabilitation therapy. Investigators will include 16 chronic stroke subjects with their optimal stimulation setup, obtained from their previous research. The participants will be computer-randomized into two equal-sized groups to receive either optimal THD-tDCS or sham stimulation, together with rehabilitation therapy (modified constraint-induced movement therapy, mCIMT) for five sessions over two weeks. Outcome measures will be collected at the baseline and right after the final intervention session. The primary outcome measure will be the change in the FM-UE score from baseline to immediately post the final intervention to assess the immediate effect of the intervention on upper extremity motor impairment. The secondary outcome measure will be the Wolf Motor Function Test time score to evaluate the immediate effect on functional motor performance.

03

Conditions studied

  • Hemiparetic Stroke

Browse trials for

Keywords

  • Upper limb
  • Stroke rehabilitation
  • Individualized intervention
  • High-definition transcranial direct current stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18 years or older
  • Must have had a stroke that resulted in paresis confined to one side. The use of a wheelchair or other assisting devices are not exclusionary.
  • Must have substantial motor impairment of the paretic upper limb
  • Absence of severe wasting or contracture or significant sensory deficits in the paretic upper limb
  • Absence of severe concurrent medical problems (e.g. cardiorespiratory impairment)
  • Fugl-Meyer Upper Extremity Score of 8-50 based on assessment performed during the baseline visit.
  • Must have had either MRI or CT of the brain performed at Carle as part of their stroke care. Imaging may have been performed either during the diagnostic work-up for stroke or as follow-up after diagnosis. The most recent images from either MRI or CT will be collected for this study.
  • Capacity to provide and participate in English (Since this study is a clinical trial and the team is yet to provide the translation service at this stage, the study is restricted to those who can consent and participate in English only).
  • Must be willing and able to perform study procedures

Exclusion criteria

Exclusion Criteria:

  • Self-reported sensitive skin or adhesive allergy as assessed by the tDCS Safety Screening Questionnaire
  • Has a cardiac pacemaker, defibrillator or an implantable cardiac resynchronization therapy device
  • Has metal implants in the head and/or brain
  • Presence of muscle tone abnormalities and motor or sensory impairment in the non-paretic limb
  • Presence of severe muscle wasting or contracture or significant sensory deficits in the paretic upper limb
  • Currently pregnant or planning to become pregnant during the study period
  • History of epilepsy, febrile convulsion, recurrent fainting spells or unexplained recurring headaches
  • Current use of illicit/recreational drugs
  • Currently undergoing anti-malarial treatment. (Note: participants can be considered for study participation after ant-malarial treatment has been discontinued)
  • Has known adverse reaction to TMS or tDCS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Active comparator
    Optimal targeted HD-tDCS + mCIMT

    Optimal targeted HD-tDCS (high-definition transcranial direct current stimulation) during Constraint Induced Movement Therapy (mCIMT)

    Device: High-definition transcranial direct stimulation: optimal · Behavioral: Modified constraint-induced movement therapy

  • Sham comparator
    Sham HD-tDCS + mCIMT

    Sham HD-tDCS (high-definition transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)

    Device: High-definition transcranial direct stimulation: sham · Behavioral: Modified constraint-induced movement therapy

Interventions

  • DeviceHigh-definition transcranial direct stimulation: sham

    High-definition transcranial direct stimulation with zero stimulation intensity (placebo)

  • DeviceHigh-definition transcranial direct stimulation: optimal

    High-definition transcranial direct stimulation with individualized, optimal parameters.

  • BehavioralModified constraint-induced movement therapy

    Modified Constraint-Induced Movement Therapy (mCIMT) is an evidence-based neurorehabilitation approach that improves upper limb function after stroke or brain injury by restricting the unaffected limb while intensively training the affected limb.

06

What researchers measure

Primary outcomes

  1. Change in the Fugl-Meyer Upper Extremity score from baseline

    Fugl-Meyer Upper Extremity (FM-UE) is a measure of motor impairment (0 to 66 points, with higher points indicating less impairment). FM-UE scale consists of a 33-item assessment which provides a global assessment of upper extremity motor impairment. A rater provides an ordinal rating (2=near normal ability/response, 1=partial ability, 0=unable to perform/no response) for each item.

    Time frame: Right after the final intervention session

Secondary outcomes

  1. Change in the Wolf Motor Function Test Time Score From Baseline

    Wolf Motor Function (WMFT) Test is a measure of functional motor activity that quantifies upper extremity motor ability through timed and functional tasks. The WMFT Time Score the median of 15 timed arm movements and hand dexterity tasks, each to be completed up to 120s. If a task could not be completed in 120s, a score of 121s was assigned. Higher score indicates a worse motor function.

    Time frame: Right after the final intervention session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — I will follow American Heart Association Open Science Policy to share IPD: https://professional.heart.org/en/research-programs/awardee-resources/open-science-policy-statements-for-aha-funded-research

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Please refer to https://professional.heart.org/en/research-programs/awardee-resources/open-science-policy-statements-for-aha-funded-research for detailed information in term of time-frame of sharing such data

Access criteria: Please refer to https://professional.heart.org/en/research-programs/awardee-resources/open-science-policy-statements-for-aha-funded-research for detailed information in term of access criteria

Data sharing details ↗ · professional.heart.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Mar 2027, 4 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 4 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Start moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 20, 2026
StartActual
Nov 9, 2026was Jul 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Carle Foundation Hospital is now Recruiting
Nov 10, 2026
Start date
Jul 1, 2026→Nov 9, 2026 (actual)
moved 2 times, Oct 21, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Carle Foundation Hospital is now Recruiting
    Start date Nov 15, 2026→Nov 9, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 21, 2026
    Start date Jul 1, 2026→Nov 15, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07599774
Lead sponsor
Carle Foundation Hospital
Collaborators
American Heart Association
Responsible party
Yuan Yang (Associate Professor, Carle Foundation Hospital) — Principal investigator
First posted
May 20, 2026
Start date
Nov 9, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Yuan Yang, PhD, MS
Contact
yuan.yang@carle.com
217-244-5870
Sanjiv Jain, MD
Contact
sanjiv.jain@carle.com
217-383-3800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion